background
dissemin
fatal
zika
viru
zikv
infect
report
immunosuppress
patient
exist
interferonsignalingreceptordefici
mous
model
may
suitabl
evalu
treatment
effect
recombin
interferon
method
develop
novel
mous
model
zikv
infect
immunosuppress
balbc
mice
dexamethason
result
dexamethasoneimmunosuppress
male
mice
week
develop
dissemin
infect
evidenc
detect
protein
express
high
viral
load
multipl
organ
weight
loss
high
clinic
score
soon
dexamethason
withdraw
dpi
warrant
euthanasia
dpi
viral
load
blood
tissu
dpi
significantli
higher
dpi
p
b
histolog
examin
reveal
promin
inflammatori
infiltr
multipl
organ
inflammatori
cell
seen
testi
find
suggest
clinic
deterior
occur
viral
clearanc
host
immun
respons
type
interferon
treatment
improv
clinic
outcom
mice
vs
surviv
conclus
besid
viru
dissemin
inflamm
variou
tissu
especi
orchiti
may
potenti
complic
zikv
infect
signific
implic
diseas
transmiss
male
fertil
interferon
treatment
consid
patient
high
risk
zikvassoci
complic
potenti
benefit
outweigh
side
effect
treatment
zika
viru
zikv
emerg
flaviviru
larg
neglect
n
year
discoveri
due
restrict
geograph
distribut
presum
low
clinic
signific
chan
et
al
sinc
largescal
outbreak
zikv
infect
occur
pacif
island
latin
america
recent
usa
southeast
asia
duffi
et
al
musso
gubler
zhu
et
al
octob
n
countriesterritori
ebiomedicin
report
continu
mosquitoborn
transmiss
zikv
world
health
organ
zika
situat
report
octob
addit
mosquitoborn
transmiss
sexual
transplacent
transmiss
zikv
also
report
chan
et
al
musso
et
al
foy
et
al
calvet
et
al
nonvectorborn
transmiss
rout
render
control
continu
epidem
complic
zikv
consid
import
human
pathogen
past
infect
adult
patient
asymptomat
develop
selflimit
acut
febril
ill
resolv
within
week
chan
et
al
duffi
et
al
howev
recent
recogn
infect
mother
may
transmit
viru
transplacent
develop
fetus
lead
congenit
malform
includ
microcephali
cerebr
malform
ophthalmolog
hear
defect
arthrogryposi
chan
et
al
mlakar
et
al
de
paula
et
al
leal
et
al
infect
adult
may
also
develop
sever
neurolog
complic
syndrom
meningoenceph
myeliti
caolormeau
et
al
carteaux
et
al
mecharl
et
al
moreov
zikvrel
fatal
increasingli
recogn
patient
fatal
infect
underli
medic
condit
markedli
immunosuppress
includ
patient
system
lupu
erythematosu
rheumatoid
arthriti
corticosteroid
therapi
die
dissemin
infect
detect
zikv
rna
blood
brain
spleen
liver
kidney
lung
heart
obtain
postmortem
examin
pan
american
health
organizationworld
health
ogan
pahowho
sarmientoospina
et
al
arzuzaortega
et
al
number
anim
model
develop
studi
pathogenesi
evalu
countermeasur
zikv
infect
rhesu
macaqu
subcutan
zikv
inocul
develop
mild
clinic
sign
resembl
selflimit
ill
infect
immunocompet
adult
dudley
et
al
nonhuman
primat
model
provid
robust
platform
evalu
vaccin
host
immun
respons
abbink
et
al
howev
mild
clinic
diseas
primat
suboptim
antivir
treatment
evalu
moreov
expertis
facil
work
nonhuman
primat
avail
research
laboratori
wildtyp
adult
balbc
mice
suscept
intraperiton
zikv
inocul
dick
suckl
young
mice
intracerebr
zikv
inocul
develop
diseas
local
central
nervou
system
dick
way
et
al
weinbren
william
bell
et
al
pregnant
mice
fetal
mice
partial
intact
type
interferon
signal
respons
fetus
femal
mice
deficienct
type
interferon
signal
respons
cross
wildtyp
male
mice
use
studi
pathogenesi
pregnanc
maternalfet
transmiss
model
technic
demand
miner
et
al
cugola
et
al
type
iii
interferonsign
receptordefici
mice
intraperiton
subcutan
zikv
inocul
develop
fatal
dissemin
infect
lazear
et
al
dowal
et
al
aliota
et
al
rossi
et
al
model
use
evalu
countermeasur
zikv
infect
protect
effect
antivir
drug
vaccin
easili
observ
treat
mice
howev
model
completenearcomplet
defici
interferon
respons
resembl
real
clinic
situat
immunosuppress
human
moreov
mice
suboptim
studi
host
immun
respons
may
expens
laboratori
resourcelimit
area
limit
knowledg
gap
develop
character
readili
avail
mous
model
resembl
immunosuppress
host
dissemin
infect
show
mice
develop
inflamm
multipl
organ
includ
test
may
import
implic
zikv
longterm
outcom
effect
fertil
also
util
novel
anim
model
show
earli
treatment
clinic
approv
recombin
type
interferon
improv
clinic
outcom
mice
clinic
isol
zikv
puerto
rico
strain
kindli
provid
brandi
russel
barbara
johnson
center
diseas
control
prevent
usa
viru
amplifi
three
addit
passag
vero
cell
atcc
minimum
essenti
medium
mem
supplement
fetal
calf
serum
unitsml
penicillin
plu
streptomycin
make
work
stock
viru
viru
titrat
aliquot
zikv
appli
confluent
vero
cell
plate
tissu
cultur
infecti
dose
tcid
assay
previous
describ
slight
modif
zhou
et
al
briefli
serial
dilut
zikv
inocul
vero
cell
monolay
quadrupl
cultur
penicillinstreptomycinsuppl
mem
plate
observ
cytopath
effect
day
viral
titer
calcul
reed
endpoint
method
one
tcid
interpret
amount
viru
caus
cytopath
effect
inocul
well
approv
obtain
committe
use
live
anim
teach
research
univers
hong
kong
male
femal
balbc
mice
week
old
obtain
laboratori
anim
unit
univers
hong
kong
mice
kept
biosafeti
hous
given
access
standard
pellet
feed
water
ad
libitum
viru
inocul
experi
perform
biosafeti
anim
facil
accord
standard
oper
procedur
approv
committe
use
live
anim
teach
research
univers
hong
kong
describ
previous
zhang
et
al
mice
randomli
divid
group
given
differ
regimen
viru
inocul
dexamethason
recombin
interferon
treatment
tabl
phosphatebuff
salin
pb
use
dilut
viru
stock
desir
concentr
inocula
backtitr
verifi
dose
given
day
viru
inocul
dose
viru
equival
tcid
plaqu
form
unit
pb
inocul
via
intraperiton
rout
mice
ketamin
mgkg
xylazin
mgkg
anesthesia
mice
negativecontrol
group
group
inject
volum
pb
mice
monitor
three
time
day
clinic
sign
diseas
numer
score
assign
observ
previous
describ
dowal
et
al
graham
et
al
bodi
weight
surviv
monitor
day
postinocul
dpi
euthanasia
three
mice
group
except
group
includ
mockinfect
control
mice
without
dexamethason
immunosuppress
group
includ
zikvinocul
dexamethasoneimmunosuppress
mice
without
dexamethason
withdraw
sacrif
dpi
virolog
histolog
immunohistochemistri
analys
remain
mice
sacrif
dpi
euthan
weight
loss
weight
loss
clinic
sign
dowal
et
al
sampl
brain
testi
epididymi
male
prostat
male
ovaryuteru
femal
kidney
urinari
bladder
spleen
liver
pancrea
intestin
heart
lung
salivari
gland
collect
necropsi
specimen
separ
two
part
one
immedi
fix
pbsbuffer
formalin
immedi
frozen
experi
blood
sampl
also
collect
rna
extract
realtim
pcr
analysi
paraffinembed
tissu
cut
section
mount
slide
stain
hematoxylin
eosin
h
e
light
microscopi
examin
previous
describ
zheng
et
al
immunohistochem
stain
antigen
mous
antiserum
protein
prepar
previous
describ
use
primari
antibodi
chan
et
al
deparaffin
rehydr
tissu
section
treat
antigen
unmask
solut
accord
manufactur
instruct
vector
laboratori
inc
burlingam
ca
usa
stain
mous
mous
polym
ihc
kit
abcam
cambridg
unit
kingdom
primari
antibodi
mous
antiserum
dilut
bsapb
incub
overnight
follow
mous
mous
hrp
polym
kit
abcam
horseradish
peroxidaseconjug
secondari
antibodi
min
color
develop
perform
use
dab
vector
laboratori
burlingam
ca
usa
immunohistochem
stain
section
incub
overnight
primari
antibodi
rabbit
antimous
rat
antimous
abcam
antigen
unmask
block
follow
incub
biotinconjug
goat
antirabbit
igg
goat
antirat
igg
calbiochem
darmstadt
germani
min
room
temperatur
streptavidinperoxidas
complex
reagent
vector
laboratori
ad
incub
room
temperatur
min
color
develop
done
dab
vector
laboratori
tissu
section
examin
microscop
two
pathologist
operatorblind
manner
imag
captur
imag
system
equip
spotadv
comput
softwar
total
nucleic
acid
tna
extract
blood
necropsi
tissu
use
viru
mini
kit
qiasymphoni
dsp
viruspathogen
mini
kit
qiagen
hilden
germani
respect
previous
describ
zheng
et
al
chan
et
al
chan
et
al
zikv
envelop
gene
measur
use
quantinova
probe
rtpcr
kit
qiagen
lightcycl
realtim
pcr
system
roch
diagnost
basel
switzerland
purifi
tna
amplifi
contain
quantinova
probe
rtpcr
master
mix
qn
probe
rtmix
forward
primer
revers
primer
nm
probe
forward
primer
revers
primer
probe
target
zikv
envelop
gene
previous
describ
use
chan
et
al
reaction
incub
min
follow
min
thermal
cycl
cycl
intern
control
gene
measur
use
quantinova
sybr
green
rtpcr
kit
qiagen
lightcycl
realtim
pcr
system
purifi
tna
amplifi
contain
quantinova
sybr
green
rtpcr
master
mix
qn
sybr
green
rtmix
forward
primer
revers
primer
gene
reaction
incub
min
follow
min
thermal
cycl
cycl
seri
dilut
equival
copiesreact
mixtur
prepar
gener
standard
curv
run
parallel
test
sampl
data
analyz
graphpad
prism
softwar
graphpad
softwar
inc
kaplanmei
surviv
curv
analyz
log
rank
test
weight
loss
compar
use
twoway
anova
student
ttest
use
determin
signific
differ
viru
titer
tukeykram
post
hoc
test
use
discern
differ
among
individu
treatment
group
previous
report
rossi
et
al
pvalu
consid
statist
signific
establish
novel
mous
model
zikv
infect
compar
clinic
histolog
virolog
find
male
group
femal
group
mice
dexamethason
immunosuppress
zikv
inocul
appropri
control
group
tabl
term
clinic
paramet
dexamethasoneimmunosuppress
mice
develop
mild
weight
loss
fig
mortal
dpi
fig
c
weight
loss
dexamethasoneimmunosuppress
mice
zikv
inocul
group
tabl
eleven
group
mice
receiv
differ
regimen
viru
inocul
dexamethason
antivir
treatment
studi
group
gender
rout
inoculum
zikv
dpi
dexamethason
antivir
treatment
b
date
sacrificeeuthanasia
ip
tcid
mgkg
ip
day
dpi
inclus
n
n
dpi
c
f
ip
tcid
mgkg
ip
day
dpi
inclus
n
n
dpi
ip
tcid
n
n
dpi
f
ip
tcid
n
n
dpi
mgkg
ip
day
dpi
inclus
n
n
dpi
f
mgkg
ip
day
inclus
n
n
dpi
n
dpi
ip
tcid
mgkg
ip
day
dpi
inclus
n
dpi
ip
tcid
mgkg
ip
day
dpi
inclus
pegyl
iudos
sc
dpi
n
n
dpi
ip
tcid
mgkg
ip
day
dpi
inclus
iudos
ip
dpi
n
n
dpi
abbrevi
dpi
day
postinocul
f
femal
ifn
interferon
ip
intraperiton
male
sc
subcutan
weekold
balbc
mice
use
group
b
prepar
pegyl
use
studi
pegintron
merck
co
inc
whitehous
station
nj
usa
betaferon
bayer
schere
pharma
ag
berlin
germani
respect
c
mice
group
euthan
dpi
weight
loss
clinic
symptom
consist
signific
compar
includ
zikvinocul
mice
without
dexamethason
immunosuppress
group
mockinfect
mice
without
dexamethason
immunosuppress
group
start
dpi
p
b
minim
histolog
chang
inflammatori
infiltr
seen
tissu
male
femal
mice
dexamethason
immunosuppress
zikv
inocul
group
hand
protein
express
detect
immunohistochem
stain
tissu
mice
dexamethasoneimmunosuppress
mice
mock
infect
group
suggest
viral
protein
express
specif
relat
dexamethason
effect
fig
dexamethasoneimmunosuppress
mice
zikv
inocul
group
also
high
mean
viral
load
blood
tissu
dpi
especi
testisepididymi
ovaryuteru
prostat
spleen
pancrea
fig
b
b
find
dpi
suggest
dissemin
nonleth
zikv
infect
involv
differ
organ
minim
inflammatori
respons
due
dexamethason
immunosuppress
investig
possibl
effect
immun
reconstitut
dexamethasoneimmunosuppress
mice
dexamethason
stop
dpi
led
promin
weight
loss
increas
symptom
dexamethasoneimmunosuppress
mice
group
promin
bodi
weight
loss
observ
male
mice
dexamethason
immunosuppress
zikv
inocul
group
mice
weight
loss
dpi
fig
femal
mice
dexamethason
immunosuppress
zikv
inocul
group
also
progress
weight
loss
weight
loss
dpi
contrast
none
mice
dexamethason
immunosuppress
day
day
postinfect
group
develop
abrupt
weight
loss
dpi
dpi
fig
weight
loss
mice
group
becam
consist
compar
control
group
group
includ
dexamethasoneimmunosuppress
mice
mock
infect
group
sinc
dpi
p
b
togeth
find
suggest
combin
immun
reconstitut
dexamethason
withdraw
dissemin
viru
infect
respons
abrupt
clinic
deterior
mice
group
develop
rapid
breath
lethargi
andor
ruffl
fur
sinc
dpi
group
dpi
group
shortli
dexamethason
stop
fig
reason
earlier
onset
weight
loss
symptom
male
mice
fulli
understood
might
relat
higher
cumul
dose
dexamethason
higher
baselin
bodi
weight
andor
possibl
effect
androgen
viru
replic
tian
et
al
base
predefin
criteria
male
femal
mice
euthan
dpi
dpi
respect
fig
compar
mice
control
group
group
either
gain
weight
b
weight
loss
spontan
recoveri
dpi
fig
remain
asymptomat
fig
surviv
studi
period
fig
euthanasia
dpi
h
e
stain
necropsi
tissu
mice
show
promin
acut
inflammatori
reaction
predominantli
lymphocyt
infiltr
promin
inflammatori
chang
seen
brain
cortic
parenchym
perivascular
lymphocyt
infiltr
fig
c
kidney
acut
tubul
interstiti
inflamm
fig
f
testi
necrot
hemorrhag
seminifer
tubul
mark
lymphocyt
infiltr
perimet
tubul
interstitium
fig
protein
express
still
visibl
lesser
degre
immunohistochem
stain
testisepididymi
ovaryuteru
kidney
spleen
small
intestin
pancrea
salivari
gland
dexamethasoneimmunosuppress
mice
zikv
inocul
dpi
compar
dpi
contrast
inflammatori
reaction
viral
protein
express
seen
organ
control
mice
zikv
inocul
alon
group
dexamethason
immunosuppress
alon
group
fig
find
confirm
mice
zikv
inocul
dexamethason
immunosuppress
suscept
infect
previous
report
histolog
chang
model
mice
group
unrel
dexamethasoneinduc
effect
druginduc
testicular
toxic
lazear
et
al
dowal
et
al
aliota
et
al
rossi
et
al
khorsandi
et
al
absenc
inflammatori
infiltr
zikvinocul
dexamethasoneimmunosuppress
mice
without
dexamethason
withdraw
group
support
role
host
immun
respons
elicit
clinic
histolog
chang
zikvinocul
mice
dexamethason
withdraw
group
confirm
presenc
inflammatori
infiltr
character
cell
type
involv
host
immun
respons
stain
necropsi
testi
dexamethasoneimmunosuppress
mice
zikv
inocul
dexamethasoneimmunosuppress
mockinfect
control
mice
panleukocyt
cytotox
lymphocyt
antibodi
corrobor
histolog
find
testi
dexamethasoneimmunosuppress
mice
zikv
inocul
control
mice
stain
posit
fig
f
antibodi
fig
h
find
confirm
presenc
inflammatori
infiltr
especi
lymphocyt
testi
zikvinfect
mice
dexamethasoneimmunosuppress
mice
zikv
inocul
group
also
significantli
lower
mean
viral
load
blood
tissu
euthanasia
dpi
compar
collect
dpi
log
dpi
fig
b
b
euthanasia
dpi
viral
rna
still
detect
tissu
male
mice
log
viremia
absent
control
mice
zikv
inocul
dexamethason
immunosuppress
undetect
viral
rna
blood
tissu
consist
previou
report
lazear
et
al
dowal
et
al
aliota
et
al
rossi
et
al
overal
find
suggest
multiorgan
inflamm
upon
immun
reconstitut
partial
viral
clearanc
mice
withdraw
dexamethason
immunosuppress
next
evalu
effect
recombin
type
interferon
treatment
mous
model
use
male
mice
earlier
onset
weight
loss
clinic
symptom
requir
necropsi
dpi
mice
treat
pegyl
merck
co
inc
whitehous
station
nj
usa
iudos
everi
h
subcutan
dpi
dpi
dpi
group
bayer
schere
pharma
ag
berlin
germani
iudos
everi
h
intraperiton
dpi
dpi
dpi
dpi
dpi
group
shown
fig
mice
treat
pegyl
group
group
weight
loss
spontan
recoveri
dpi
weight
loss
untreat
group
becam
significantli
mice
treat
either
start
dpi
p
b
mice
remain
asymptomat
surviv
studi
period
fig
c
none
tissu
show
promin
inflammatori
reaction
h
e
stain
dpi
dpi
protein
express
rare
seen
immunohistochem
stain
testisepididymi
kidney
spleen
small
intestin
lung
pancrea
collect
dpi
testi
epididymi
kidney
spleen
dpi
reduc
mean
viral
load
blood
tissu
log
compar
untreat
mice
dpi
dpi
fig
b
reduct
signific
tissu
high
viral
load
spleen
testi
pancrea
prostat
p
b
overal
find
suggest
earli
use
system
recombin
type
interferon
improv
clinic
histolog
virolog
paramet
mice
dissemin
zikv
infect
full
spectrum
clinic
manifest
complic
zikv
infect
remain
incomplet
understood
today
previou
assumpt
zikv
infect
entir
selflimit
diseas
without
sever
longlast
sequela
overturn
increas
recognit
congenit
malform
neurolog
complic
immunemedi
thrombocytopenia
even
fatal
immunosuppress
patient
pan
american
health
organ
b
fig
viral
load
blood
major
organ
dexamethasoneimmunosuppress
balbc
male
femal
mice
zikv
inocul
mice
male
dpi
n
two
independ
experi
dpi
n
two
independ
experi
b
femal
dpi
n
two
independ
experi
dpi
n
two
independ
experi
dexamethason
immunosuppress
higher
blood
tissu
viral
load
dpi
dexamethason
euthanasia
dpi
male
mice
dpi
femal
mice
dexamethason
stop
dpi
zikv
rna
copi
blood
tissu
mice
determin
realtim
rtpcr
normal
describ
text
denot
pvalu
denot
pvalu
error
bar
repres
standard
error
mean
world
health
ogan
pahowho
sarmientoospina
et
al
arzuzaortega
et
al
duijster
et
al
notabl
patient
sever
nonpregnancyrel
complic
zikv
often
deterior
suddenli
initi
mild
diseas
phase
viral
load
began
decreas
caolormeau
et
al
mecharl
et
al
sarmientoospina
et
al
led
us
hypothes
like
mani
flaviviru
infect
includ
yellow
fever
dengu
west
nile
viru
infect
host
immun
respons
may
also
play
role
zikvassoci
complic
especi
viral
clearanc
phase
host
immun
system
quaresma
et
al
screaton
et
al
wang
et
al
studi
character
novel
readili
avail
mous
model
sever
zikv
infect
attempt
provid
altern
venu
studi
host
immun
respons
evalu
countermeasur
zikv
infect
find
studi
import
implic
pathogenesi
potenti
complic
treatment
zikv
infect
dexamethasoneimmunosuppress
mice
zikv
inocul
studi
develop
dissemin
infect
viremia
multiorgan
involv
includ
brain
urogenit
tract
intestin
liver
spleen
pancrea
heart
lung
salivari
gland
evid
protein
express
immunohistochem
stain
andor
detect
viral
load
tissu
immunohistochemistri
stain
testi
confirm
presenc
inflammatori
cell
infiltr
panleukocyt
marker
predominantli
lymphocyt
clinic
male
mice
develop
earlier
onset
diseas
femal
mice
weight
loss
clinic
sign
warrant
euthanasia
dpi
weight
loss
clinic
score
histolog
evid
inflammatori
reaction
sever
soon
dexamethason
withdraw
viral
load
alreadi
decreas
log
overal
find
suggest
like
relat
flavivirus
host
immun
respons
might
led
mark
clinic
deterior
face
dissemin
zikv
infect
time
immunemedi
clearanc
viru
began
find
provid
addit
explan
pathogenesi
fatal
zikv
infect
propos
relat
uncontrol
viru
dissemin
previous
describ
mous
model
util
type
iii
interferonsignalingreceptordefici
mice
unabl
mount
robust
host
innat
immun
respons
mous
model
also
use
studi
zikv
tissu
tropism
potenti
complic
sever
zikv
infect
addit
report
find
detect
viru
particl
andor
rna
brain
spinal
cord
kidney
spleen
liver
testi
ovari
heart
lung
muscl
blood
type
iii
interferonsignalingreceptordefici
mice
zikv
infect
studi
identifi
intestin
pancrea
salivari
gland
possibl
tissu
anatom
site
viru
infect
dick
lazear
et
al
dowal
et
al
aliota
et
al
rossi
et
al
tissu
tropism
zikv
mous
model
concur
invitro
observ
zikv
effici
replic
divers
cell
type
neuron
testicular
prostat
renal
intestin
hepat
placent
origin
chan
et
al
brault
et
al
hugh
et
al
degre
viru
dissemin
multiorgan
involv
also
compat
clinic
find
patient
sever
andor
fatal
zikv
infect
viral
particl
andor
rna
detect
multipl
organ
postmortem
examin
pan
american
health
organizationworld
health
ogan
pahowho
sarmientoospina
et
al
arzuzaortega
et
al
inflammatori
neurolog
complic
syndrom
meningoenceph
myeliti
recent
report
patient
zikv
infect
inflammatori
disord
nonneuron
tissu
well
recogn
caolormeau
et
al
carteaux
et
al
mecharl
et
al
find
show
inflamm
could
observ
multipl
organ
includ
testi
kidney
spleen
liver
intestin
pancrea
lung
salivari
gland
outsid
nervou
system
among
nonneuron
tissu
inflammatori
reaction
promin
testi
model
mice
patient
zikv
infect
report
hematospermia
pelvic
pain
dysuria
detect
viral
particl
andor
rna
semen
chan
et
al
musso
et
al
foy
et
al
histolog
evid
orchiti
report
due
difficulti
obtain
patient
testicular
tissu
histolog
examin
previou
mous
fig
repres
histolog
find
brain
kidney
dexamethasoneimmunosuppress
balbc
mice
zikv
inocul
dexamethasoneimmunosuppress
mockinfect
control
mice
brain
kidney
sacrif
mice
examin
organ
entir
embed
one
paraffin
block
one
fullfac
paraffin
section
maximum
diamet
organ
examin
per
block
section
brain
dpi
dexamethasoneimmunosuppress
mous
zikv
inocul
show
moder
degre
perivascular
lymphocyt
infiltr
b
mark
lymphocyt
infiltr
cortic
parenchyma
h
e
origin
magnif
section
brain
dpi
dexamethasoneimmunosuppress
mockinfect
mous
show
normal
architectur
parenchyma
c
h
e
origin
magnif
section
kidney
dpi
show
acut
tubul
larg
amount
inflammatori
exud
tubular
lumen
e
moder
degre
interstiti
inflamm
h
e
origin
magnif
f
section
kidney
dpi
dexamethasoneimmunosuppress
mockinfect
mous
show
normal
architectur
h
e
origin
magnif
model
zikv
infect
util
type
iii
interferonsignalingreceptordefici
mice
also
show
viral
particl
rna
could
detect
mice
test
histolog
analysi
report
lazear
et
al
markedli
necrot
hemorrhag
seminifer
tubul
observ
mice
highli
alarm
orchiti
may
longterm
effect
fertil
chang
account
dexamethasoneinduc
testicular
toxic
morpholog
differ
latter
present
test
control
mice
dexamethason
treatment
mock
infect
khorsandi
et
al
revis
work
similar
find
report
test
mice
treat
block
monoclon
antibodi
inocul
zikv
clinic
studi
confirm
presenc
orchiti
assess
fertil
convalesc
male
patient
conduct
ascertain
longterm
consequ
zikv
infect
regard
reproduct
hormon
derang
inflamm
organ
acut
tubul
interstiti
nephriti
sialaden
hepat
enter
acut
pancreat
report
patient
zikv
flaviviru
infect
chan
et
al
sarmientoospina
et
al
arzuzaortega
et
al
duijster
et
al
bonaldo
et
al
gourinat
et
al
musso
et
al
mercado
et
al
bhagat
et
al
torr
et
al
macnamara
chatterje
et
al
potenti
complic
may
increasingli
recogn
zikv
epidem
continu
expand
develop
countri
larg
age
immunosuppress
popul
final
mous
model
also
provid
novel
avenu
evalu
antizikv
treatment
type
interferon
broadspectrum
antivir
activ
includ
zikv
type
interferonsignalingreceptordefici
mice
suitabl
evalu
effect
recombin
type
interferon
therefor
evalu
antivir
effect
two
commerci
avail
prepar
recombin
type
interferon
new
mous
model
hamel
et
al
zumla
et
al
chan
et
al
chan
et
al
show
earli
use
either
drug
associ
improv
clinic
outcom
fatal
fatal
untreat
mice
markedli
decreas
inflammatori
respons
dexamethason
withdraw
reduc
viral
load
variou
tissu
mice
compar
untreat
mice
viral
load
reduct
especi
signific
earli
phase
diseas
dpi
mice
dexamethason
find
suggest
earli
use
recombin
interferon
might
help
control
viral
replic
initi
phase
infect
prevent
subsequ
develop
sever
complic
relat
exagger
immun
respons
presenc
high
viral
load
seen
untreat
mice
import
confirm
result
mous
model
use
differ
zikv
strain
clinic
trial
zikv
antagon
mous
less
effici
human
thu
may
suscept
type
interferon
mice
grant
et
al
patient
mild
zikv
infect
may
requir
system
interferon
treatment
clinic
trial
consid
evalu
benefit
earli
use
interferon
treatment
patient
risk
develop
sever
zikvassoci
complic
underli
comorbid
sarmientoospina
et
al
increas
risk
fetal
loss
low
birth
weight
associ
interferon
therapi
first
trimest
pregnanc
may
outweigh
risk
congenit
malform
due
zikv
infect
optim
time
treatment
commenc
investig
late
commenc
interferon
treatment
may
useless
deleteri
avoid
solomon
et
al
summari
novel
mous
model
use
investig
host
immun
responseassoci
damag
evalu
countermeasur
zikv
infect
inflamm
differ
viscer
organ
may
import
complic
zikv
studi
infect
human
longterm
monitor
testicular
function
zikvinfect
male
patient
consid
clinic
trial
inc
whitehous
station
nj
usa
iudos
everi
h
subcutan
dpi
dpi
dpi
bayer
schere
pharma
ag
berlin
germani
iudos
everi
h
intraperiton
dpi
dpi
dpi
dpi
dpi
interferon
treatment
group
n
treatment
group
n
treatment
group
n
result
combin
two
independ
experi
pvalu
indic
interferon
treatment
versu
treatment
interferon
treatment
versu
treatment
abbrevi
ifn
interferon
clinic
score
normal
ruffl
fur
lethargi
pinch
hunch
wasp
waist
labor
breath
rapid
breath
inact
neurolog
immobil
consid
evalu
effect
recombin
interferon
treatment
patient
high
risk
zikvassoci
complic
potenti
benefit
may
outweight
side
effect
treatment
supplementari
data
articl
found
onlin
http
dx
jfwc
ajz
ccsc
kyy
design
studi
ajz
ccsc
hz
vkmp
perform
infect
ccyy
jolt
kkhc
khc
prepar
viru
stock
viral
titrat
ajz
wwnm
vkmp
rkhay
prepar
histolog
immunohistochemistri
slide
ccyy
kmt
zz
jpc
perform
viral
load
studi
jfwc
ajz
rkhay
vkmp
kyy
acquir
imag
microscop
analyz
quantifi
data
fy
khk
dyj
provid
technic
assist
edit
manuscript
jfw
ajz
kyy
wrote
manuscript
jasper
fw
chan
receiv
travel
grant
pfizer
corpor
hong
kong
astella
pharma
hong
kong
corpor
limit
invit
speaker
gilead
scienc
hong
kong
limit
author
declar
conflict
interest
fund
sourc
role
studi
design
data
collect
analysi
interpret
write
report
correspond
author
full
access
data
studi
final
respons
decis
submit
public
grate
li
andrew
chakyiu
lee
shuofeng
yuan
facilit
studi
work
partli
support
donat
larri
chikin
yung
hui
hoy
chow
sin
lan
chariti
fund
limit
fund
consult
servic
enhanc
b
fig
viral
load
blood
major
organ
dexamethasoneimmunosuppress
balbc
mice
zikv
inocul
without
recombin
type
interferon
treatment
male
mice
treatment
reduc
zikv
blood
tissu
viral
load
compar
untreat
mice
dpi
n
per
group
two
independ
experi
b
dpi
n
per
group
two
independ
experi
zikv
rna
copi
blood
tissu
mice
determin
realtim
rtpcr
normal
describ
text
denot
pvalu
error
bar
repres
standard
error
mean
